Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study
Initiating T-DXd within 2 months post-ICI may enhance therapeutic efficacy in HER2-positive AGC without affecting safety, supporting a potential sequencing option after ICI therapy.
Authors
- Keita Yamaguchi
- Akitaka Makiyama
- Rin Inamoto
- Keiko Minashi (ORCID: https://orcid.org/0000-0003-1513-7117)
- Motohisa Hagiwara
- Motohiro Imano (ORCID: https://orcid.org/0000-0003-2242-4245)
- Takeshi Kawakami
- Yasuhiro Kodera
- H. Kume
- Tomohiro Nishina
- H. Kawakami
- S. Morita
- Y. Narita
- Wataru Hashimoto
- Koki Nakanishi
- Hirotaka Konishi
- Naotoshi Sugimoto
- Kei Muro
Institutions
- Daiichi Sankyo (Germany) (DE)
- Tohoku University (JP)
- Kyoto University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Shizuoka Cancer Center (JP)
- Osaka International Cancer Institute (JP)
- Gifu University Hospital (JP)
- Chiba Cancer Center (JP)
- Nihonkai General Hospital (JP)
- Saitama Cancer Center (JP)
- Aichi Cancer Center (JP)
- Shikoku Cancer Center (JP)
- Nagoya Medical Center (JP)
- Nagoya University (JP)
- Kindai University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-12-27
- DOI
- https://doi.org/10.1093/jjco/hyaf216
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00